Every new paper in 280 characters, with how strong the evidence is and what readers question about it. Free to read.
Oncology · J Clin Oncol · 2026-10-12
RCTn = 898
Poppe et al. Randomized Trial of Hypofractionated Postmastectomy Radiation Therapy in Women With Breast Reconstruction (RT CHARM, Alliance A221505)Oncology · Lancet Oncol · 2026-10-09
RCTn = 98,755
Weigel et al. Invasive interval breast cancer rates after digital breast tomosynthesis plus synthesised mammography versus digital mammography screening (TOSYMA): 24-month follow-up of the multicentre, open-label, randomised, controlled, superiority trialOncology · N Engl J Med · 2026-10-01
RCTn = 373
Mayer et al. Giredestrant plus Everolimus in Advanced Breast CancerOncology · Lancet Oncol · 2026-10-01
RCTn = 810
Sun et al. Hypofractionated versus conventional fractionated postmastectomy radiotherapy for patients with high-risk breast cancer (CHN HYPOPMRT): 10-year outcomes from a randomised, non-inferiority, open-label, phase 3 trialOncology · J Clin Oncol · 2026-09-11
RCTn = 365
Zhang et al. Trastuzumab Botidotin Versus Trastuzumab Emtansine in Human Epidermal Growth Factor Receptor 2-Positive Advanced Breast Cancer: A Phase III, Open-Label, Randomized Controlled TrialOncology · Lancet Oncol · 2026-09-01
Secondary analysisn = 4,262 tumour images
Lara González et al. Manual, digital, and AI tumour-infiltrating lymphocyte scoring: a secondary analysis of the APHINITY randomised trialOncology · Ann Oncol · 2026-08-24
RCTn = 1,836
Garber et al. Sustained benefit of adjuvant olaparib in women with germline BRCA1- and BRCA2-associated high-risk HER2-negative early breast cancer: updated results from the OlympiA phase III trialOncology · Ann Oncol · 2026-07-24
Secondary analysisn = 1,556
Kalinsky et al. Ovarian reserve as a measure of adjuvant chemotherapy benefit in hormone receptor positive (HR-positive), HER2-negative, node-positive breast cancer in SWOG S1007 (RxPONDER)